Patents by Inventor Douglas MacDonald

Douglas MacDonald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230416376
    Abstract: Provided herein are antibodies and bispecific antigen-binding molecules that bind MET and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human MET. The bispecific antigen-binding molecules are capable of blocking the interaction between human MET and its ligand HGF. The bispecific antigen-binding molecules can exhibit minimal or no MET agonist activity, e.g., as compared to monovalent antigen-binding molecules that comprise only one of the antigen-binding domains of the bispecific molecule, which tend to exert unwanted MET agonist activity.
    Type: Application
    Filed: May 25, 2023
    Publication date: December 28, 2023
    Inventors: Robert Babb, Gang Chen, Christopher Daly, John DaSilva, Douglas MacDonald, Thomas Nittoli
  • Publication number: 20230340153
    Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.
    Type: Application
    Filed: April 5, 2023
    Publication date: October 26, 2023
    Inventors: Mark W. SLEEMAN, Joel H. MARTIN, Tammy T. HUANG, Douglas MACDONALD
  • Patent number: 11771762
    Abstract: The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand such as neuregulin 1. The antibodies of the invention are useful for the treatment of various cancers.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: October 3, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christopher Daly, Douglas MacDonald, Xunbao Duan
  • Publication number: 20230270837
    Abstract: The present invention provides antigen-binding proteins that specifically bind to an HLA-displayed human papillomavirus (HPV) peptide, and therapeutic and diagnostic methods of using those binding proteins.
    Type: Application
    Filed: December 15, 2022
    Publication date: August 31, 2023
    Inventors: Kevin A. Bray, Frank Delfino, Matthew C. Franklin, Elena S. Garnova, Jessica Kirshner, Douglas MacDonald, William Olson, Gavin Thurston
  • Patent number: 11608380
    Abstract: The present invention provides antibodies that bind to the class Ill variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: March 21, 2023
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jessica R. Kirshner, Douglas MacDonald, Gavin Thurston, Joel H. Martin, Frank Delfino, Thomas Nittoli, Marcus Kelly
  • Patent number: 11559576
    Abstract: The present invention provides antigen-binding proteins that specifically bind to an HLA-displayed human papillomavirus (HPV) peptide, and therapeutic and diagnostic methods of using those binding proteins.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: January 24, 2023
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Kevin A. Bray, Frank Delfino, Matthew C. Franklin, Elena S. Garnova, Jessica Kirshner, Douglas MacDonald, William Olson, Gavin Thurston
  • Publication number: 20220409732
    Abstract: Compositions comprising an MHC ligand peptide covalently attached to an MHC class II molecule are provided herein. In some compositions, the MHC ligand peptide is covalently attached to the MHC class II molecule by a peptide linker, wherein the MHC ligand peptide or the peptide linker comprises a first cysteine, wherein the MHC class II a chain or a portion thereof or the MHC class II ? chain or a portion thereof comprises a second cysteine, and wherein the first cysteine and the second cysteine form a disulfide bond such that the MHC ligand peptide is bound in a peptide-binding groove formed by the MHC class II a chain or the portion thereof and the MHC class II ? chain or the portion thereof. Also provided are nucleic acids encoding such compositions and methods for using such compositions to elicit an immune response in a subject.
    Type: Application
    Filed: December 2, 2020
    Publication date: December 29, 2022
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Douglas MacDonald, David Buckler
  • Publication number: 20220389055
    Abstract: A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.
    Type: Application
    Filed: July 19, 2022
    Publication date: December 8, 2022
    Inventors: Samuel Davis, Eric Smith, Douglas MacDonald, Kara Louise Olson
  • Publication number: 20220251215
    Abstract: The present disclosure provides antigen-binding proteins that specifically bind to an H LA-displayed New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide, and therapeutic and diagnostic methods of using those binding proteins. The antigen-binding proteins of the present disclosure bind with a high degree of specificity to HLA-displayed NY-ESO-1 and do not bind to HLA-displayed peptides that differ by 2, 3, 4, 5 or more amino acids.
    Type: Application
    Filed: July 2, 2020
    Publication date: August 11, 2022
    Inventors: Kevin A. Bray, Frank Delfino, David Dilillo, Matthew C. Franklin, Jessica Kirshner, Douglas MacDonald
  • Patent number: 11307241
    Abstract: A method is disclosed for maintaining a desired optical output in a solid state illumination device, where the device is configured to accommodate multiple light emitting diodes (LEDs) and to combine light from the LEDs to produce a single optical output. The method includes testing the LEDs before adding them into the device. The testing produces characterizing information that describes how one or more optical properties (e.g., optical power and/or peak wavelength) of the tested LED change with temperature. This characterizing information is stored in a computer-based memory of the device, and the tested LED is added (connected) into the device. Then, during operation, temperature sensors measure a temperature associated with each respective LED in the device, and electrical current to one or more of the LEDs can be adjusted based on the measured temperatures associated with each LED and its stored characterizing information.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: April 19, 2022
    Assignee: Excelitas Canada, Inc.
    Inventors: Erik Sorensen, Douglas MacDonald, Paul Constantinou, Yong Wang
  • Publication number: 20220049001
    Abstract: Provided herein are antibodies and bispecific antigen-binding molecules that bind MET and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human MET. The bispecific antigen-binding molecules are capable of blocking the interaction between human MET and its ligand HGF. The bispecific antigen-binding molecules can exhibit minimal or no MET agonist activity, e.g., as compared to monovalent antigen-binding molecules that comprise only one of the antigen-binding domains of the bispecific molecule, which tend to exert unwanted MET agonist activity.
    Type: Application
    Filed: August 25, 2021
    Publication date: February 17, 2022
    Inventors: Robert Babb, Gang Chen, Christopher Daly, John DaSilva, Douglas MacDonald, Thomas Nittoli
  • Publication number: 20220024973
    Abstract: A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.
    Type: Application
    Filed: October 7, 2021
    Publication date: January 27, 2022
    Inventors: Samuel Davis, Eric Smith, Douglas MacDonald, Kara Louise Olson
  • Publication number: 20220001000
    Abstract: The present invention provides antigen-binding proteins that specifically bind to an HLA-displayed human papillomavirus (HPV) peptide, and therapeutic and diagnostic methods of using those binding proteins.
    Type: Application
    Filed: August 13, 2020
    Publication date: January 6, 2022
    Inventors: Kevin A. Bray, Frank Delfino, Matthew C. Franklin, Elena S. Garnova, Jessica Kirshner, Douglas MacDonald, William Olson, Gavin Thurston
  • Patent number: 11168111
    Abstract: A bispecific antibody format providing ease of isolation is provided, comprising immunoglobulin heavy chain variable domains that are differentially modified in the CH3 domain, wherein the differential modifications are non-immunogenic or substantially non-immunogenic with respect to the CH3 modifications, and at least one of the modifications results in a differential affinity for the bispecific antibody for an affinity reagent such as Protein A, and the bispecific antibody is isolable from a disrupted cell, from medium, or from a mixture of antibodies based on its affinity for Protein A.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: November 9, 2021
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Samuel Davis, Eric Smith, Douglas MacDonald, Kara Louise Olson
  • Patent number: 11142578
    Abstract: Provided herein are antibodies and bispecific antigen-binding molecules that bind MET and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human MET. The bispecific antigen-binding molecules are capable of blocking the interaction between human MET and its ligand HGF. The bispecific antigen-binding molecules can exhibit minimal or no MET agonist activity, e.g., as compared to monovalent antigen-binding molecules that comprise only one of the antigen-binding domains of the bispecific molecule, which tend to exert unwanted MET agonist activity.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: October 12, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert Babb, Gang Chen, Christopher Daly, John DaSilva, Douglas MacDonald, Thomas Nittoli
  • Publication number: 20210253701
    Abstract: The present invention provides antibodies that bind to CD3 with weak or no detectable binding affinity and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with low affinity and induce human T cell proliferation and hence induce T cell-mediated killing of tumor cells with high efficacy. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3 with weak or no detectable binding affinity in an in vitro assay, and a second antigen-binding molecule that specifically binds human tumor-associated antigen. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing target antigen, such as PSMA.
    Type: Application
    Filed: March 19, 2021
    Publication date: August 19, 2021
    Inventors: Eric Smith, Lauric Haber, Robert Babb, Gang Chen, Douglas MacDonald
  • Publication number: 20210147557
    Abstract: The present invention provides antibodies that bind to the class Ill variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.
    Type: Application
    Filed: July 1, 2020
    Publication date: May 20, 2021
    Inventors: Jessica R. KIRSHNER, Douglas MACDONALD, Gavin THURSTON, Joel H. MARTIN, Frank DELFINO, Thomas NITTOLI, Marcus KELLY
  • Patent number: 10941210
    Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: March 9, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Mark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas Macdonald
  • Publication number: 20210037624
    Abstract: A method is disclosed for maintaining a desired optical output in a solid state illumination device, where the device is configured to accommodate multiple light emitting diodes (LEDs) and to combine light from the LEDs to produce a single optical output. The method includes testing the LEDs before adding them into the device. The testing produces characterizing information that describes how one or more optical properties (e.g., optical power and/or peak wavelength) of the tested LED change with temperature. This characterizing information is stored in a computer-based memory of the device, and the tested LED is added (connected) into the device. Then, during operation, temperature sensors measure a temperature associated with each respective LED in the device, and electrical current to one or more of the LEDs can be adjusted based on the measured temperatures associated with each LED and its stored characterizing information.
    Type: Application
    Filed: January 24, 2019
    Publication date: February 4, 2021
    Inventors: Erik Sorensen, Douglas MacDonald, Paul Constantinou, Yong Wang
  • Patent number: 10806780
    Abstract: The present invention provides antigen-binding proteins that specifically bind to an HLA-displayed human papillomavirus (HPV) peptide, and therapeutic and diagnostic methods of using those binding proteins.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: October 20, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kevin A. Bray, Frank Delfino, Matthew C. Franklin, Elena S. Garnova, Jessica R. Kirshner, Douglas MacDonald, William Olson, Gavin Thurston